

Table SI. Patient baseline demographics and clinical characteristics

Characteristic	Previous use of SIS (n = 85)		No previous use of SIS (n = 82)	
	Placebo (n = 40)	Dupilumab q2w (n = 45)	Placebo (n = 45)	Dupilumab q2w (n = 37)
Age, years, mean (SD)	14.5 (1.9)	14.7 (1.8)	14.4 (1.7)	14.2 (1.7)
Sex, male, n (%)	28 (70.0)	26.0 (57.8)	25 (55.6)	17 (45.9)
Weight, kg, mean (SD)	63.3 (17.6)	67.3 (25.2)	65.3 (24.6)	63.5 (23.7)
Duration of AD, years, mean (SD)	13.0 (2.91)	12.9 (3.06)	11.6 (3.76)	12.0 (2.83)
Prior use of SIS, n (%)				
Cyclosporine	20 (50.0)	19 (42.2)	NA	NA
Systemic corticosteroids	29 (72.5)	23 (51.1)	NA	NA
Methotrexate	9 (22.5)	16 (35.6)	NA	NA
Azathioprine	0	2 (4.4)	NA	NA
Mycophenolate	2 (5.0)	4 (8.9)	NA	NA
Other ^a	9 (22.5)	11 (24.4)	NA	NA
EASI score [0–72], mean (SD) ^b	38.5 (15.29)	39.1 (15.23)	32.9 (12.27)	30.6 (10.36)
Patients with IGA score, n (%)				
IGA=3 (moderate)	13 (32.5)	19 (42.2)	26 (57.8)	20 (54.1)
IGA=4 (severe)	27 (67.5)	26 (57.8)	19 (42.2)	17 (45.9)
Peak pruritus NRS score, [0–10], mean (SD) ^b	7.7 (1.70)	7.7 (1.56)	7.8 (1.56)	7.3 (1.45)
BSA of AD affected, [0–100], %, mean (SD) ^b	62.6 (24.30)	62.6 (21.50)	50.9 (22.85)	48.0 (18.60)
SCORAD score, [0–103], mean (SD) ^b	72.1 (13.3)	73.4 (15.2)	68.9 (13.2)	67.1 (11.4)
POEM score, [0–28], mean (SD) ^b	22.3 (4.8)	21.8 (5.0)	20.0 (5.7)	19.9 (4.8)
CDLQI score, [0–30], mean (SD) ^b	14.2 (7.0)	13.1 (5.9)	12.2 (6.4)	12.9 (6.6)

^aThe patient form only collected the use information of "Other" SIS as 1 option, thus no more detailed information can be analysed. ^bScore ranges: low scores indicate good quality of life and better disease control in each case.

AD: atopic dermatitis; BSA: body surface area; CDLQI: Children's Dermatology Life Quality Index; EASI: Eczema Area and Severity Index; IGA: Investigator's Global Assessment; NA: not available; NRS: numerical rating scale; POEM: Patient-Oriented Eczema Measure; SCORAD: SCORing Atopic Dermatitis; SD: standard deviation; SIS: systemic immunosuppressants; q2w: every 2 weeks.